Recro to Present at H.C. Wainwright BioConnect 2022 Conference
03 Janvier 2022 - 1:00PM
Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development
and manufacturing organization (CDMO) dedicated to solving complex
formulation and manufacturing challenges primarily in small
molecule therapeutic development, today announced that its chief
executive officer, David Enloe, will deliver a corporate
presentation as part of the H.C. Wainwright BioConnect 2022
Conference. The conference, which will take place January 10-13,
2022, is being conducted with a virtual format.
Details for the corporate presentation are as
follows:
- H.C. Wainwright BioConnect
2022 ConferenceConference Dates: January 10-13,
2022Presentation Timing: Available online upon start of conference
on Monday, January 10, 2022Format: Virtual conference; webcast
available
To access the webcast of the presentation,
please do so by visiting the “Events” page in the Investor section
of the Company’s website, www.recrocdmo.com. An archived
webcast will be available on the Company’s website for 30 days.
About RecroRecro (NASD: REPH)
is a bi-coastal contract development and manufacturing organization
(CDMO) with capabilities spanning pre-Investigational New Drug
(IND) development to commercial manufacturing and packaging for a
wide range of therapeutic dosage forms with a primary focus in the
area of small molecules. With an expertise in solving complex
manufacturing problems, Recro is a leading CDMO providing
therapeutic development, end-to-end regulatory support, clinical
and commercial manufacturing, aseptic fill/finish, lyophilization,
packaging and logistics services to the global pharmaceutical
market.
In addition to our experience in handling DEA
controlled substances and developing and manufacturing
modified-release dosage forms, Recro has the expertise to deliver
on our clients’ pharmaceutical development and manufacturing
projects, regardless of complexity level. We do all of this in our
best-in-class facilities, which total 145,000 square feet, in
Gainesville, Georgia and San Diego, California.
For more information about Recro’s CDMO
solutions, visit recrocdmo.com.
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Ryan D. Lake (CFO)
Recro
770-531-8365
ryan.lake@recroCDMO.com
Recro Pharma (NASDAQ:REPH)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
Recro Pharma (NASDAQ:REPH)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025